

REMARKS

In the Office Action of June 30, 2008, the Examiner has divided the claims into fifteen groups,

- I. Claims 1-16 drawn to a method of treating or preventing cancer using compounds drawn to Formula II where M_1 – M_4 = carbons to form a benzene ring (may be substituted) and R_1 = aryl group which may be substituted.
- II. Claims 1-16 drawn to a method of treating or preventing cancer using compounds drawn to Formula II where M_1 – M_4 = carbons to form a benzene ring (may be substituted) and R_1 = a benzyl group ($-CH_2Ph$), which may be substituted.
- III. Claims 1-16 drawn to compounds of Formula II that are not embraced by groups I-II.
- IV. Claims 1-16 drawn to a method of treating or preventing cancer using compounds drawn to Formula IV where M_1 – M_4 = carbons to form a benzene ring (may be substituted) and M_5 – M_{14} = carbons to form a naphthalene ring which may be substituted.
- V. Claims 1-16 drawn to a method of treating or preventing cancer using compounds drawn to Formula V where M_1 – M_4 = carbons to form a benzene ring (may be substituted) and M_5 – M_{14} = carbons to form a naphthalene ring which may be substituted.

- VI. Claims 1-16 drawn to compounds of Formula IV and V that are not embraced by groups IV-V.
- VII. Claims 1-16 drawn to a method of treating or preventing cancer using compounds drawn to Formula IX where $M_{25}-M_{28}$ = carbons to form a seven-membered ring.
- VIII. Claims 1-16 drawn to a method of treating or preventing cancer using compounds drawn to Formula IX that is not embraced by group VII.
- IX. Claims 1-16 drawn to a method of treating or preventing cancer using compounds drawn to Formula X where M_x = carbons to form a benzene ring (may be substituted), R_9 = aryl group (may be substituted) and R_8 and R_9 does not form a cyclic structure.
- X. Claims 1-16 drawn to a method of treating or preventing cancer using compounds drawn to Formula X that is not embraced by group IX.
- XI. Claims 1-16 drawn to a method of treating or preventing cancer using compounds drawn to Formula XI where M_x = carbons to form a piperazine ring and R_{10} = a furanyl ring.
- XII. Claims 1-16 drawn to a method of treating or preventing cancer using compounds drawn to Formula XI where M_x = carbons to form a piperazine ring and R_{10} = a thiényl ring.
- XIII. Claims 1-16 drawn to a method of treating or preventing cancer using compounds drawn to Formula XI that are not embraced by groups XI—XII.

XIV. Claims 1-16 drawn to a method of treating or preventing cancer using compounds drawn to Formula XII.

XV. Claims 17-22 drawn to a method of treating or preventing MUC1-positive cancers.

XVI. Claim 23 drawn to a method for diagnosing cancer cells.

Applicants traverse this requirement. Reconsideration and withdrawal thereof are earnestly requested.

Applicants submit that there is not an undue burden placed upon the Examiner to search and consider all of the claims.

All of the compounds and their use are related as a single invention concept.

However, in order to be responsive to the outstanding Restriction Requirement, Applicants provisionally elect to prosecute Group XV, claims 17-22 drawn to a method of treating or preventing MUC1-positive cancers, for prosecution on the merits, with traverse.

Accordingly, early examination on the merits is respectfully requested.

The Commissioner is authorized to charge JHK Law's Deposit Account No. **502486** for any fees required under 37 CFR §§ 1.16 and 1.17 that are not covered, in whole or in part, by a check enclosed herewith and to credit any overpayment to said Deposit Account No. **502486**.

Respectfully submitted,

JHK Law

Dated: October 30, 2008

By: /Joseph Hyosuk Kim/
Joseph Hyosuk Kim, Ph.D.
Reg. No. 41,425

P.O. Box 1078
La Canada, CA 91012-1078
(818) 249-8177 – direct
(818) 249-8277 - fax